Johnson Johnson Company Top Insiders
JNJ Stock | USD 163.63 0.61 0.37% |
Nearly 77 percent of all Johnson Johnson's insiders are aggressively buying. The analysis of insiders' sentiment of trading Johnson Johnson stock suggests that many insiders are very bullish at this time. Johnson Johnson employs about 138.1 K people. The company is managed by 50 executives with a total tenure of roughly 224 years, averaging almost 4.0 years of service per executive, having 2762.0 employees per reported executive.
Jennifer Taubert Chairman Executive Vice President - Worldwide Chairman, Pharmaceuticals |
Ashley McEvoy Chairman Executive Vice President - Worldwide Chairman, Medical Devices |
Insider Sentiment 77
Aggressively Buying
Selling | Buying |
Latest Trades
2025-02-25 | Robert J Decker | Disposed 6999 @ 165.88 | View | ||
2025-02-24 | Jefferson Shreve | Acquired @ 163.81 | |||
2025-02-18 | Timothy Schmid | Disposed 403 @ 156.15 | View | ||
2025-01-24 | Josh Gottheimer | Acquired @ 146.76 | |||
2025-01-21 | Josh Gottheimer | Acquired @ 148.1 | |||
2025-01-16 | Josh Gottheimer | Acquired @ 147.78 | |||
2025-01-08 | Marjorie Taylor Greene | Acquired @ 142.1 | |||
2024-12-31 | Kevin Hern | Disposed @ 144.62 | |||
2024-12-24 | Marjorie Taylor Greene | Acquired @ 145.85 | |||
2024-12-12 | Josh Gottheimer | Acquired @ 146.23 | |||
2024-12-10 | Lloyd Doggett | Acquired @ 149.26 | |||
2024-12-06 | Virginia Foxx | Acquired @ 149.28 | |||
2024-11-26 | Josh Gottheimer | Acquired @ 154.51 | |||
2024-11-25 | Marjorie Taylor Greene | Acquired @ 155.75 | |||
2024-11-22 | Josh Gottheimer | Acquired @ 155.14 | |||
2024-11-08 | Jared Moskowitz | Acquired @ 155.62 | |||
2024-10-29 | Tommy Tuberville | Disposed @ 160.14 | |||
2024-09-10 | Lloyd Doggett | Acquired @ 167.38 |
Monitoring Johnson Johnson's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of Johnson Johnson's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Johnson Johnson. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Johnson Johnson's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Johnson |
Johnson Johnson's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Johnson Johnson's future performance. Based on our forecasts, it is anticipated that Johnson will maintain a workforce of nearly 138100 employees by April 2025.Johnson Johnson's latest congressional trading
Congressional trading in companies like Johnson Johnson, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Johnson Johnson by those in governmental positions are based on the same information available to the general public.
2025-03-10 | Representative Jefferson Shreve | Acquired $15K to $50K | Verify | ||
2025-02-12 | Representative Gil Cisneros | Acquired Under $15K | Verify | ||
2025-02-11 | Representative Josh Gottheimer | Acquired Under $15K | Verify | ||
2025-01-28 | Representative Marjorie Taylor Greene | Acquired Under $15K | Verify | ||
2025-01-16 | Representative Kevin Hern | Acquired $100K to $250K | Verify | ||
2025-01-15 | Representative Josh Gottheimer | Acquired Under $15K | Verify | ||
2025-01-09 | Representative Lloyd Doggett | Acquired Under $15K | Verify | ||
2025-01-07 | Representative Virginia Foxx | Acquired Under $15K | Verify | ||
2024-12-30 | Representative Marjorie Taylor Greene | Acquired Under $15K | Verify | ||
2024-12-09 | Representative Jared Moskowitz | Acquired Under $15K | Verify | ||
2024-12-06 | Representative Ro Khanna | Acquired Under $15K | Verify | ||
2024-12-05 | Representative Josh Gottheimer | Acquired Under $15K | Verify | ||
2024-11-28 | Representative Marjorie Taylor Greene | Acquired Under $15K | Verify | ||
2024-11-14 | Senator Tommy Tuberville | Acquired $15K to $50K | Verify | ||
2024-10-11 | Representative Lloyd Doggett | Acquired Under $15K | Verify | ||
2024-09-06 | Representative John James | Acquired Under $15K | Verify | ||
2024-08-20 | Senator Sheldon Whitehouse | Acquired $15K to $50K | Verify | ||
2024-08-16 | Representative Kathy Manning | Acquired Under $15K | Verify | ||
2024-08-08 | Representative Richard W Allen | Acquired $15K to $50K | Verify | ||
2024-07-10 | Representative Richard W Allen | Acquired $15K to $50K | Verify | ||
2024-01-16 | Senator Jerry Moran | Acquired Under $15K | Verify | ||
2023-11-15 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
2023-10-20 | Senator Pete Ricketts | Acquired $100K to $250K | Verify | ||
2023-10-02 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
2023-09-22 | Senator Dan Sullivan | Acquired Under $15K | Verify | ||
2023-09-17 | Senator Dan Sullivan | Acquired Under $15K | Verify | ||
2022-11-12 | Senator Shelley Moore Capito | Acquired Under $15K | Verify | ||
2022-02-03 | Senator Thomas R Carper | Acquired Under $15K | Verify | ||
2021-10-18 | Representative Robert J Wittman | Acquired Under $15K | Verify | ||
2021-02-12 | Representative Austin Scott | Acquired $15K to $50K | Verify | ||
2020-08-25 | Representative Bob Gibbs | Acquired Under $15K | Verify | ||
2019-02-14 | Representative John A Yarmuth | Acquired Under $15K | Verify |
Johnson Johnson Management Team Effectiveness
The company has Return on Asset of 0.0813 % which means that on every $100 spent on assets, it made $0.0813 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2006 %, implying that it generated $0.2006 on every 100 dollars invested. Johnson Johnson's management efficiency ratios could be used to measure how well Johnson Johnson manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Johnson Johnson's Return On Tangible Assets are relatively stable compared to the past year. Return On Capital Employed is expected to hike to 0.25 this year, although the value of Return On Assets will most likely fall to 0.13. At this time, Johnson Johnson's Total Current Liabilities is relatively stable compared to the past year. Liabilities And Stockholders Equity is expected to hike to about 202.3 B this year, although the value of Change To Liabilities is projected to rise to (962.5 M).The value of Common Stock Shares Outstanding is expected to pull down to about 2.2 B. The value of Net Income Applicable To Common Shares is expected to pull down to about 13 B
Johnson Johnson Workforce Comparison
Johnson Johnson is currently regarded as number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 473,800. Johnson Johnson totals roughly 138,100 in number of employees claiming about 29% of equities under Health Care industry.
Johnson Johnson Profit Margins
The company has Net Profit Margin of 0.16 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.18 %, which entails that for every 100 dollars of revenue, it generated $0.18 of operating income.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.77 | 0.79 |
|
| |||||
Net Profit Margin | 0.39 | 0.37 |
|
| |||||
Operating Profit Margin | 0.18 | 0.25 |
|
| |||||
Pretax Profit Margin | 0.17 | 0.16 |
|
| |||||
Return On Assets | 0.13 | 0.24 |
|
| |||||
Return On Equity | 0.48 | 0.46 |
|
|
Johnson Johnson Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Johnson Johnson insiders, such as employees or executives, is commonly permitted as long as it does not rely on Johnson Johnson's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Johnson Johnson insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-03-01 | 0.8438 | 81 | 96 | 1,316,210 | 743,267 |
2024-12-01 | 4.0 | 4 | 1 | 70,378 | 68,835 |
2024-09-01 | 0.8 | 4 | 5 | 15,935 | 35,906 |
2024-06-01 | 3.2 | 16 | 5 | 64,664 | 69,533 |
2024-03-01 | 0.9367 | 74 | 79 | 1,126,871 | 841,041 |
2023-12-01 | 0.5 | 1 | 2 | 227.97 | 12,388 |
2023-09-01 | 0.25 | 2 | 8 | 14,927 | 64,213 |
2023-06-01 | 4.3333 | 13 | 3 | 89,364 | 12,520 |
2023-03-01 | 1.1064 | 52 | 47 | 1,560,338 | 1,435,117 |
2022-12-01 | 0.0563 | 17 | 302 | 424,982 | 808,031 |
2022-06-01 | 0.75 | 6 | 8 | 1,639 | 121,198 |
2022-03-01 | 0.6949 | 82 | 118 | 1,591,197 | 1,210,521 |
2021-12-01 | 1.0 | 4 | 4 | 5,804 | 22,640 |
2021-06-01 | 1.5 | 3 | 2 | 767.89 | 912.00 |
2021-03-01 | 1.3559 | 80 | 59 | 1,535,897 | 616,920 |
2020-12-01 | 1.0 | 4 | 4 | 55,444 | 130,274 |
2020-09-01 | 1.4 | 7 | 5 | 19,996 | 61,230 |
2020-03-01 | 1.0 | 90 | 90 | 2,022,671 | 1,394,742 |
2019-12-01 | 1.0 | 3 | 3 | 7,366 | 4,034 |
2019-09-01 | 1.0 | 1 | 1 | 382.39 | 2,692 |
2019-06-01 | 2.0 | 2 | 1 | 3,350 | 353.00 |
2019-03-01 | 1.0615 | 69 | 65 | 1,211,043 | 1,102,350 |
2018-12-01 | 0.7895 | 15 | 19 | 506,509 | 1,029,964 |
2018-09-01 | 0.2727 | 3 | 11 | 29,684 | 66,041 |
2018-06-01 | 2.0 | 2 | 1 | 757.75 | 385.00 |
2018-03-01 | 1.098 | 56 | 51 | 1,459,455 | 1,396,495 |
2017-12-01 | 1.0 | 4 | 4 | 76,454 | 119,787 |
2017-09-01 | 1.0 | 6 | 6 | 288,991 | 575,950 |
2017-06-01 | 4.0 | 4 | 1 | 1,313 | 409.00 |
2017-03-01 | 1.1077 | 72 | 65 | 2,208,599 | 1,395,624 |
2016-09-01 | 1.5 | 6 | 4 | 45,606 | 88,162 |
2016-06-01 | 0.8571 | 6 | 7 | 8,522 | 23,649 |
2016-03-01 | 1.2292 | 59 | 48 | 1,810,647 | 1,592,510 |
2015-12-01 | 0.8 | 8 | 10 | 72,335 | 128,397 |
2015-06-01 | 1.8 | 9 | 5 | 232,452 | 415,933 |
2015-03-01 | 1.7931 | 52 | 29 | 1,497,466 | 863,712 |
2014-12-01 | 1.625 | 13 | 8 | 124,081 | 80,120 |
2014-09-01 | 3.3333 | 10 | 3 | 31,463 | 60,936 |
2014-06-01 | 1.8571 | 13 | 7 | 26,671 | 50,018 |
2014-03-01 | 2.2273 | 49 | 22 | 1,595,007 | 270,290 |
2013-12-01 | 2.0 | 24 | 12 | 43,879 | 88,621 |
2013-09-01 | 1.5 | 18 | 12 | 151,479 | 218,390 |
2013-06-01 | 4.5 | 9 | 2 | 1,681 | 7,429 |
2013-03-01 | 2.8947 | 55 | 19 | 1,861,702 | 242,918 |
2012-12-01 | 1.3333 | 24 | 18 | 88,061 | 242,611 |
2012-09-01 | 1.3333 | 12 | 9 | 359,037 | 708,892 |
2012-03-01 | 3.8 | 38 | 10 | 2,001,830 | 1,040,386 |
2011-12-01 | 1.4 | 14 | 10 | 355,881 | 705,544 |
2011-06-01 | 2.0 | 8 | 4 | 331,325 | 658,300 |
2011-03-01 | 2.8333 | 34 | 12 | 1,078,290 | 147,164 |
2010-12-01 | 2.4 | 12 | 5 | 23,846 | 41,538 |
2010-09-01 | 1.5 | 12 | 8 | 268,351 | 529,534 |
2010-06-01 | 9.0 | 9 | 1 | 21,323 | 18,000 |
2010-03-01 | 3.3333 | 30 | 9 | 1,019,440 | 123,426 |
2009-12-01 | 1.3846 | 18 | 13 | 114,643 | 230,603 |
2009-09-01 | 2.1429 | 15 | 7 | 188,410 | 411,810 |
2009-06-01 | 2.75 | 11 | 4 | 41,599 | 80,840 |
2009-03-01 | 2.2381 | 47 | 21 | 1,229,737 | 244,806 |
2008-12-01 | 2.8571 | 20 | 7 | 76,055 | 98,292 |
2008-09-01 | 7.0 | 14 | 2 | 5,454 | 6,000 |
2008-06-01 | 0.5714 | 20 | 35 | 138,992 | 270,000 |
2008-03-01 | 4.8889 | 44 | 9 | 1,089,570 | 110,445 |
2007-12-01 | 0.9444 | 17 | 18 | 32,542 | 59,287 |
2007-09-01 | 11.0 | 11 | 1 | 2,422 | 2,640 |
2007-06-01 | 14.0 | 14 | 1 | 4,734 | 1,700 |
2007-03-01 | 4.6667 | 42 | 9 | 1,050,227 | 237,274 |
2006-12-01 | 0.8095 | 17 | 21 | 222,057 | 437,806 |
2006-09-01 | 1.4375 | 23 | 16 | 163,933 | 293,054 |
2006-06-01 | 2.2857 | 16 | 7 | 22,169 | 51,600 |
2006-03-01 | 7.1429 | 50 | 7 | 1,414,193 | 45,960 |
2005-12-01 | 2.0 | 18 | 9 | 72,595 | 95,869 |
2005-09-01 | 2.375 | 19 | 8 | 18,256 | 30,989 |
2005-06-01 | 4.4 | 22 | 5 | 68,622 | 109,600 |
2005-03-01 | 3.9 | 39 | 10 | 1,183,947 | 201,708 |
2004-12-01 | 3.3333 | 20 | 6 | 8,068 | 10,700 |
2004-09-01 | 1.9167 | 23 | 12 | 141,147 | 203,523 |
2004-06-01 | 5.5 | 22 | 4 | 52,068 | 89,200 |
2004-03-01 | 3.4737 | 66 | 19 | 1,467,963 | 540,524 |
2003-12-01 | 1.0 | 34 | 34 | 156,218 | 407,761 |
2003-09-01 | 7.3333 | 22 | 3 | 18,738 | 18,979 |
2003-06-01 | 4.3333 | 13 | 3 | 3,404 | 125,200 |
2003-03-01 | 1.0 | 1 | 1 | 26.00 | 13,800 |
Johnson Johnson Notable Stakeholders
A Johnson Johnson stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Johnson Johnson often face trade-offs trying to please all of them. Johnson Johnson's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Johnson Johnson's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Jennifer Taubert | Executive Vice President - Worldwide Chairman, Pharmaceuticals | Profile | |
Ashley McEvoy | Executive Vice President - Worldwide Chairman, Medical Devices | Profile | |
Alex Gorsky | Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee | Profile | |
Joaquin Duato | Executive Vice President Worldwide Chairman - Pharmaceuticals | Profile | |
Thibaut Mongon | Executive Vice President, Worldwide Chairman, Consumer Health | Profile | |
Paulus Stoffels | Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee | Profile | |
Jasmina Brooks | President Webster | Profile | |
Michael Sneed | Executive Vice President - Global Corporate Affairs and Chief Communication Officer | Profile | |
Kathryn Wengel | Executive Vice President Chief Global Supply Chain Officer | Profile | |
James Swanson | Executive Vice President, Chief Information Officer | Profile | |
Joseph Wolk | Chief Financial Officer, Executive Vice President | Profile | |
Peter Fasolo | Chief Human Resource Officer, Executive Vice President | Profile | |
Joseph CPA | Executive CFO | Profile | |
Ronald Williams | Independent Director | Profile | |
Anne Mulcahy | Lead Independent Director | Profile | |
Ian Davis | Independent Director | Profile | |
Mark Weinberger | Independent Director | Profile | |
Jennifer Doudna | Independent Director | Profile | |
Marillyn Hewson | Independent Director | Profile | |
Mary Beckerle | Independent Director | Profile | |
Darius Adamczyk | Independent Director | Profile | |
Hubert Joly | Independent Director | Profile | |
Mark McClellan | Independent Director | Profile | |
Charles Prince | Independent Director | Profile | |
Michael Ullmann | VP, General Counsel and Member of Executive Committee | Profile | |
Duane Arsdale | Treasurer | Profile | |
Nadja West | Independent Director | Profile | |
Mark Larkins | Worldwide Secretary | Profile | |
Joanne MD | Chief Officer | Profile | |
Vanessa Broadhurst | Executive Vice President Global Corporate Affairs | Profile | |
Tom Cavanaugh | Company Medicine | Profile | |
D Davis | Independent Director | Profile | |
A Washington | Independent Director | Profile | |
Dirk Brinckman | Chief Officer | Profile | |
Elizabeth JD | Executive Officer | Profile | |
Michael Bodner | Global Recovery | Profile | |
Susan MD | Vice Officer | Profile | |
Hani Abouhalka | Company Digital | Profile | |
Ahmet Tezel | Group RD | Profile | |
Frederic MD | Chief Group | Profile | |
Robert Decker | Controller Officer | Profile | |
Mathai Mammen | Executive Vice President Pharmaceuticals, R&D | Profile | |
Timothy Schmid | Executive MedTech | Profile | |
William Hait | Executive Vice President Chief External Innovation, Medical Safety, Global Public Health Officer | Profile | |
Jessica Moore | Vice Relations | Profile | |
Celine Martin | Group CSS | Profile | |
Kristen Mulholland | Executive Officer | Profile | |
Elizabeth Forminard | Executive Counsel | Profile | |
Guy MD | Group EMEA | Profile | |
David Lee | Immunology Head | Profile |
About Johnson Johnson Management Performance
The success or failure of an entity such as Johnson Johnson often depends on how effective the management is. Johnson Johnson management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Johnson management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Johnson management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.33 | 0.34 | |
Return On Capital Employed | 0.22 | 0.25 | |
Return On Assets | 0.24 | 0.13 | |
Return On Equity | 0.46 | 0.48 |
Johnson Johnson Workforce Analysis
Traditionally, organizations such as Johnson Johnson use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Johnson Johnson within its industry.Johnson Johnson Manpower Efficiency
Return on Johnson Johnson Manpower
Revenue Per Employee | 643.2K | |
Revenue Per Executive | 1.8B | |
Net Income Per Employee | 101.9K | |
Net Income Per Executive | 281.3M | |
Working Capital Per Employee | 40.3K | |
Working Capital Per Executive | 111.4M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Johnson Stock please use our How to buy in Johnson Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Johnson Johnson. If investors know Johnson will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Johnson Johnson listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.03) | Dividend Share 4.91 | Earnings Share 5.79 | Revenue Per Share | Quarterly Revenue Growth 0.053 |
The market value of Johnson Johnson is measured differently than its book value, which is the value of Johnson that is recorded on the company's balance sheet. Investors also form their own opinion of Johnson Johnson's value that differs from its market value or its book value, called intrinsic value, which is Johnson Johnson's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Johnson Johnson's market value can be influenced by many factors that don't directly affect Johnson Johnson's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Johnson Johnson's value and its price as these two are different measures arrived at by different means. Investors typically determine if Johnson Johnson is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Johnson Johnson's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.